Background: The use of antimullerian hormone (AMH) as a marker of ovarian reserve may contribute to treatment decisions regarding the use of medications with known gonadotoxic effects. This study aimed to assess ovarian reserve by measuring AMH level in premenopausal SLE patients. Subjects and methods: A case control study, included 60 female subjects (30 SLE patients and 30 apparently healthy subjects). Full history taking and examination were carried out in Rheumatology and Rehabilitation Department. Laboratory investigations were conducted in Clinical Pathology Department, Faculty of Medicine, Zagazig University Hospitals. Antimullerian hormone level was measured in both patients and controls. Results: The study included 30 SLE female patients whose ages ranged from 19-50 years with a mean of 32.23 ± 8.846 years. The control group composed of 30 healthy female volunteers, whose ages ranged from 18 - 42 years and a mean of 29.03 ± 7.837 years. The mean of the disease duration was 6.87 ± 4.313 years. The study showed that the median of AMH level in SLE group was 2.7 (0.1-9.7) vs. 3.07 (0.3 – 20) in the control group, p value = 0.146 (P>0.05), therefore there was no statistically significant difference between both groups regarding AMH levels or between serum AMH and different drug use. Conclusion: AMH did not differ between SLE patients and controls & was not affected by the disease duration or activity. Moreover, immunosuppressive agents such as cyclophosphamide, azathioprine and mycophenolate mofetil did not significantly affect the AMH levels in SLE patients.